Related Experiment Video
Updated: Sep 9, 2025
10:56
Combining Human Organoids and Organ-on-a-Chip Technology to Model Intestinal Region-Specific Functionality
Published on: May 5, 2022
13.9K
Development of NAFLD-Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy
Xiao-Yan You1,2,3, Xiang-Yang Li1,2,3, Hui Wang2,4
1Henan Engineering Research Center of Food Microbiology, College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
Cell Proliferation
|August 28, 2025
Summary
Semaglutide effectively treats non-alcoholic fatty liver disease (NAFLD) in a human liver organoid model. This glucagon-like peptide-1 (GLP-1) receptor agonist reduces fat accumulation and inflammation, offering a promising therapeutic strategy for NAFLD.
Area of Science:
- Hepatology and Pharmacology
- Stem Cell Biology and Organoid Technology
- Metabolic Disease Research
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a progressive condition with severe complications and limited treatment options.
- Glucagon-like peptide-1 (GLP-1) receptor agonists, like semaglutide, show potential beyond diabetes and obesity management.
- Novel therapeutic strategies are urgently needed to address the unmet medical needs in NAFLD treatment.
Purpose of the Study:
- To evaluate the efficacy of semaglutide in a human liver organoid (hLO) model of NAFLD.
- To investigate the underlying mechanisms of semaglutide's action in NAFLD.
- To establish a reliable in vitro platform for preclinical NAFLD drug screening.
Main Methods:
- Human induced pluripotent stem cells (hiPSCs) were differentiated into functional hLOs using microengineered array chips.
- NAFLD was induced in hLOs through exposure to free fatty acids (FFAs), mimicking steatosis, inflammation, and fibrogenesis.
- Semaglutide treatment (50 nM) was applied to assess its impact on NAFLD hallmarks.
Main Results:
- Semaglutide significantly reduced FFA-induced lipid deposition, lowering triglyceride levels 8-fold and cholesterol levels 1.8-fold.
- Treatment with semaglutide decreased pro-inflammatory markers (IL-6, IL-8, TNF-α) by 1.5-2 fold.
- Semaglutide increased the expression of lipolytic genes by approximately 45%.
Conclusions:
- Semaglutide demonstrates significant therapeutic potential in ameliorating key NAFLD pathologies within a human liver organoid model.
- The study validates a robust in vitro platform for evaluating novel NAFLD interventions.
- Findings support the clinical translation of GLP-1-based therapies for NAFLD, addressing a critical unmet need.
